Navigation Links
Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water
Date:4/12/2013

Fairfax, VA (PRWEB) April 12, 2013

As part of its respected in-depth tracking of bio/pharmaceutical industry trends, PharmSource Information Services, Inc. (PharmSource) has just released its annual report analyzing NDA approvals for 2012 and approval trends for the 2006-2012 period.

Geared to bio/pharma contract manufacturers, as well as to bio/pharmaceutical company procurement executives making sourcing decisions, this proprietary 10-page analysis gives critical insight into evolving contract manufacturing trends and developments, and provides an in-depth data-driven analysis, giving a “who’s who” of contract manufacturing organizations (CMOs) that have received NDA approvals and how they stack up. The report includes data and analysis on several leading indicators including:

  •     Approvals by dosage form, including solid dose, injectable and semisolid/liquid. Data for 2012 is compared against the 2006-2011 trends.
  •     Analysis of the distribution of approvals by sponsor type (small, generic, self-sustaining, global), including data on sponsor types for large molecule vs. small molecule approvals. It includes data on the share of approvals type that were outsourced in 2012 for each sponsor, as well as the 2006-2011 average.
  •     The share of NDA approvals that were outsourced over the period from 2006 to 2012, including a comparison of new molecular entities (NMEs) vs. other NDAs.
  •     Data on the top 19 CMOs that received NDA approvals in 2012, and their comparative approval performance during the 2005-2012 period.
  •     2012 NDA approvals with dose CMOs, including 34 products by sponsor, dosage form, approval type, dose contractors and API contractors.

This report is available by subscription to PharmSource’s Strategic Advantage platform, which includes access to all of PharmSource’s intelligence briefings and in-depth syndicated reports, as well as to its global database of contract manufacturers. It also is available as a stand-alone report. For more information, contact PharmSource directly at +1-703-383-4903 / info[at]pharmsource[dot]com.

About PharmSource
PharmSource brings together buyers and sellers of contract services for the development of drugs, medical devices and diagnostics. A trusted provider of global market and business intelligence since 1996, PharmSource publishes reports and databases, and conducts surveys and analyses related to industry contract service activities and trends.

PharmSource contact information:
+1-703-383-4903 Phone (USA, eastern time-zone)
info(at)pharmsource(dot)com
http://www.pharmsource.com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10625157.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
2. Number of Ion Community Users Triples, Spurred by Open Access to DNA Sequencing Protocols and Analysis Software
3. Magnetic actuation enables nanoscale thermal analysis
4. Strategic Analysis of the Collagen Peptide Market in the United States
5. Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Psychemedics Corporation Receives New, Additional FDA Clearances for Hair Analysis Drug Testing
8. Webinar Announcement: GenomeSpace: A New Solution for Integrating Genomic Analysis Tools
9. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
10. Spectrometry Market (Atomic, Molecular and Mass Spectrometry) - Global Scenario, Trends, Industry Analysis, Size, Share & Forecast 2011 - 2017
11. New wave of technologies possible after ground-breaking analysis tool developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):